clinical data acquisition News
-
ABBOTT INFORMATICS LAUNCHES STARLIMS PUBLIC HEALTH SOLUTION PH12.0
Hollywood, FL - Abbott Informatics is pleased to announce the launch of the STARLIMS Public Health Solution PH12.0. Abbott Informatics has the STARLIMS Public Health (PH) Solution product currently deployed in laboratories throughout the United States. Nevertheless, enhancements need to continuously be added in order for our product to satisfy evolving market needs. Newborn screening is one such ...
-
Screening Subjects for Diabetic Peripheral Neuropathy
How much do you know about the development of your favorite products? What about the devices you encounter at your doctor’s office? So much of the work that goes into every single thing we use remains unseen by the user or consumer, from concept development to design to ...
-
Check-Cap Announces Expansion of Manufacturing Capacity and Production Line to Support U.S. Pivotal Study Initiation
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the expansion of C-Scan's manufacturing capacity and on-premise production ...
-
Imaging Driven Innovation
Learn more about recent advances and software tools to leverage medical imaging data in the product lifecycle. Are you new to working with medical imaging data as an engineer? First you should find out if you will have access to DICOM or an other 3D or 4D medical imaging data format. If so, the complete range of software solutions are potentially available to you. If not, it’s not the ...
By Echobio, LLC
-
STALICLA announces first patients enrolled in EU/US multicenter data collection biosampling study
The launch of the STA-B-001 study will accelerate the recruitment of participants for STP1 and STP2 Phase 2 trials. The multicenter trial will also enable deep clinical and biological data collection to strengthen STALICLA’s platform. Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine ...
By STALICLA
-
Clinical study authorised in Sweden for the investigation of CDNF and Renishaw drug delivery system in Parkinson`s patients
The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc's randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw's chronic drug delivery system, in Parkinson's patients. The first study site to start patient recruitment will be the Karolinska University Hospital in Stockholm, ...
By Renishaw plc
-
Carlsmed and the International Spine Study Group Foundation Announce Long-term Partnership
CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc., a commercial stage medical device technology company, is announcing today that it has partnered with the International Spine Study Group Foundation (ISSGF), the premier study group on adult spinal deformity, to collect data on surgical treatment with personalized interbody devices. Long term outcomes data will be collected to assess the role of ...
-
Focussing on Australia`s second biggest killer
The cluster will conduct the START (Stroke, imaging, pRevention and Treatment) cohort study of stroke which is designed to integrate imaging and biomarker analysis to identify patients at risk of stroke. Those strategies will then be used to develop preventative measures for those patients. The START Cohort will collect and analyse information derived from brain imaging and blood samples taken ...
-
Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
Enrollment completion for the first Phase 3 clinical trial in microbiome industry Largest randomized, double-blinded study, with over 300 patients enrolled aimed to demonstrate the potential benefit of RBX2660 in reducing rates of recurrent Clostridioides difficile (C. diff) infection Rebiotix intends to use the results from the Phase 3 trial to serve as the basis for licensure application to ...
-
Second Heart Assist Announces Successful Completion of Long-Duration Pre-Clinical Studies
NEWS PROVIDED BY Second Heart Assist, Inc. June 22nd, 2020 7:00am ET Salt Lake City, Utah, June 22nd, 2020 /PRDistribution/ — Second Heart Assist Inc., inventors of the first, true, aortic stent-based circulatory assist pump intended primarily for use in heart failure patients, announces the successful completion of a series of long-duration preclinical studies in pulsatile mock loop and ...
-
Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660
Rebiotix and Ferring are the first to announce positive preliminary results on primary efficacy endpoint from ongoing pivotal Phase 3 clinical trial for RBX2660 RBX2660 is an investigational, non-antibiotic, microbiome-based therapy, developed to reduce Clostridioides difficile (C. diff) infection recurrences CDC defines C. diff as a major burden to patients and doctors and an urgent ...
-
Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD
Health Canada approved the amendment of the phase I study to assess the effect of low and moderate doses of inhaled CBD in healthy cannabinoid users. The collaboration with the CRCHUM will allow Tetra to obtain phase I clinical data on inhaled CBD. OTTAWA, ON, March 8, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in ...
-
A Brand New Collaboration Between Emovi and The Geneva Foundation
In partnership with The Geneva Foundation and supporting grant from the Quebec Ministry of Economy and Innovation, Emovi will launch the 24-month clinical project within US Army clinics at Fort Bragg and High Point University, North Carolina, USA Emovi, Inc., a leading medical device developer and manufacturer for orthopaedics, announced today a clinical collaboration with the US Army in ...
By Emovi
-
IlluminOss Medical Completes Enrollment for U.S. Clinical Trial Using Groundbreaking Photodynamic Bone Stabilization System
IlluminOss Medical, a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced it has completed enrollment in its first U.S. clinical trial towards FDA approval of its IlluminOss System, the world’s first and only system of its kind which supports the treatment of fractures using patient-specific intramedullary ...
-
Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan, the first and only patient-friendly, preparation-free, screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's ...
-
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is the first microbiota-based live biotherapeutic to demonstrate efficacy as early as first recurrence of Clostridioides difficile (C. difficile) infection RBX2660 Phase 3 data add to the world’s largest and most robust clinical program ever conducted in ...
-
GeneCentric Therapeutics Identifies RNA-Based Genomic Markers of Clinical Response in Lung Cancer
The Piedmont Study, a Real-World Data Analysis in Patients Treated with Platinum Doublet Chemotherapy and/or Pembrolizumab, Identifies Predictive Biomarkers for Approved First-Line Treatments in NSCLC DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the completion of its Piedmont ...
-
GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles to anti-PD-(L)1 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you